WO2015179473A1 - Stents with anchoring sections - Google Patents
Stents with anchoring sections Download PDFInfo
- Publication number
- WO2015179473A1 WO2015179473A1 PCT/US2015/031691 US2015031691W WO2015179473A1 WO 2015179473 A1 WO2015179473 A1 WO 2015179473A1 US 2015031691 W US2015031691 W US 2015031691W WO 2015179473 A1 WO2015179473 A1 WO 2015179473A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- stent
- disc
- valve
- expanded condition
- prosthetic heart
- Prior art date
Links
- 238000004873 anchoring Methods 0.000 title claims abstract description 41
- 210000003709 heart valve Anatomy 0.000 claims abstract description 61
- 230000007704 transition Effects 0.000 claims abstract description 10
- 239000000463 material Substances 0.000 claims description 16
- 229910001000 nickel titanium Inorganic materials 0.000 claims description 5
- HLXZNVUGXRDIFK-UHFFFAOYSA-N nickel titanium Chemical compound [Ti].[Ti].[Ti].[Ti].[Ti].[Ti].[Ti].[Ti].[Ti].[Ti].[Ti].[Ni].[Ni].[Ni].[Ni].[Ni].[Ni].[Ni].[Ni].[Ni].[Ni].[Ni].[Ni].[Ni].[Ni] HLXZNVUGXRDIFK-UHFFFAOYSA-N 0.000 claims description 5
- 210000004115 mitral valve Anatomy 0.000 abstract description 27
- 210000005246 left atrium Anatomy 0.000 description 17
- 210000005240 left ventricle Anatomy 0.000 description 16
- 238000000034 method Methods 0.000 description 7
- 210000001519 tissue Anatomy 0.000 description 7
- 230000001746 atrial effect Effects 0.000 description 6
- 210000001765 aortic valve Anatomy 0.000 description 5
- 230000006870 function Effects 0.000 description 5
- 238000013459 approach Methods 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 230000017531 blood circulation Effects 0.000 description 4
- 239000011248 coating agent Substances 0.000 description 4
- 238000000576 coating method Methods 0.000 description 4
- 238000002513 implantation Methods 0.000 description 4
- 238000007789 sealing Methods 0.000 description 4
- 210000000591 tricuspid valve Anatomy 0.000 description 4
- 210000003484 anatomy Anatomy 0.000 description 3
- 239000004744 fabric Substances 0.000 description 3
- 210000002837 heart atrium Anatomy 0.000 description 3
- 239000007943 implant Substances 0.000 description 3
- 229920000642 polymer Polymers 0.000 description 3
- 229920001343 polytetrafluoroethylene Polymers 0.000 description 3
- 239000004810 polytetrafluoroethylene Substances 0.000 description 3
- 210000005245 right atrium Anatomy 0.000 description 3
- 241000283690 Bos taurus Species 0.000 description 2
- 210000000709 aorta Anatomy 0.000 description 2
- 239000000560 biocompatible material Substances 0.000 description 2
- 210000003698 chordae tendineae Anatomy 0.000 description 2
- 210000005003 heart tissue Anatomy 0.000 description 2
- 239000002184 metal Substances 0.000 description 2
- 230000005012 migration Effects 0.000 description 2
- 238000013508 migration Methods 0.000 description 2
- 150000003673 urethanes Chemical class 0.000 description 2
- 230000002861 ventricular Effects 0.000 description 2
- 238000003466 welding Methods 0.000 description 2
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 101100289061 Drosophila melanogaster lili gene Proteins 0.000 description 1
- 102000009123 Fibrin Human genes 0.000 description 1
- 108010073385 Fibrin Proteins 0.000 description 1
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- MWCLLHOVUTZFKS-UHFFFAOYSA-N Methyl cyanoacrylate Chemical compound COC(=O)C(=C)C#N MWCLLHOVUTZFKS-UHFFFAOYSA-N 0.000 description 1
- 240000007643 Phytolacca americana Species 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 210000002376 aorta thoracic Anatomy 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 239000012620 biological material Substances 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000002297 emergency surgery Methods 0.000 description 1
- 210000001105 femoral artery Anatomy 0.000 description 1
- 229950003499 fibrin Drugs 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 238000009998 heat setting Methods 0.000 description 1
- 238000003698 laser cutting Methods 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 210000003540 papillary muscle Anatomy 0.000 description 1
- 210000003516 pericardium Anatomy 0.000 description 1
- -1 polytetrafluoroethylene Polymers 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 210000005241 right ventricle Anatomy 0.000 description 1
- 229910001285 shape-memory alloy Inorganic materials 0.000 description 1
- 239000004447 silicone coating Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 210000002435 tendon Anatomy 0.000 description 1
- 239000003106 tissue adhesive Substances 0.000 description 1
- 210000005166 vasculature Anatomy 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/02—Prostheses implantable into the body
- A61F2/24—Heart valves ; Vascular valves, e.g. venous valves; Heart implants, e.g. passive devices for improving the function of the native valve or the heart muscle; Transmyocardial revascularisation [TMR] devices; Valves implantable in the body
- A61F2/2412—Heart valves ; Vascular valves, e.g. venous valves; Heart implants, e.g. passive devices for improving the function of the native valve or the heart muscle; Transmyocardial revascularisation [TMR] devices; Valves implantable in the body with soft flexible valve members, e.g. tissue valves shaped like natural valves
- A61F2/2418—Scaffolds therefor, e.g. support stents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/02—Prostheses implantable into the body
- A61F2/24—Heart valves ; Vascular valves, e.g. venous valves; Heart implants, e.g. passive devices for improving the function of the native valve or the heart muscle; Transmyocardial revascularisation [TMR] devices; Valves implantable in the body
- A61F2/2409—Support rings therefor, e.g. for connecting valves to tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/02—Prostheses implantable into the body
- A61F2/24—Heart valves ; Vascular valves, e.g. venous valves; Heart implants, e.g. passive devices for improving the function of the native valve or the heart muscle; Transmyocardial revascularisation [TMR] devices; Valves implantable in the body
- A61F2/2427—Devices for manipulating or deploying heart valves during implantation
- A61F2/2436—Deployment by retracting a sheath
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2220/00—Fixations or connections for prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof
- A61F2220/0008—Fixation appliances for connecting prostheses to the body
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2230/00—Geometry of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof
- A61F2230/0002—Two-dimensional shapes, e.g. cross-sections
- A61F2230/0028—Shapes in the form of latin or greek characters
- A61F2230/0034—D-shaped
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2230/00—Geometry of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof
- A61F2230/0063—Three-dimensional shapes
- A61F2230/0067—Three-dimensional shapes conical
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2230/00—Geometry of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof
- A61F2230/0063—Three-dimensional shapes
- A61F2230/0073—Quadric-shaped
- A61F2230/008—Quadric-shaped paraboloidal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2250/00—Special features of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof
- A61F2250/0058—Additional features; Implant or prostheses properties not otherwise provided for
- A61F2250/0069—Sealing means
Definitions
- The. present disclosure relates to heart valve replacement and, in particular, to collapsible prosthetic heart valves. More particularly, the present disclosure relates to prosthetic heart valves that facilitate secure positioning within a native valve annulus .
- Prosthetic heart, valves that are collapsible to a relatively small circumferential size can be delivered into a patient less invasively than valves that are not. collapsible.
- a collapsible valve may be delivered into a patient via a tube-like delivery apparatus such as a catheter, a trocar, a laparoscopic instrument, or the like. This collapsibility can avoid the need for a more invasive procedure such as full open chest, open heart surgery.
- Collapsible prosthetic heart valves typically take the form of a valve structure mounted on a stent.
- a stent There are two types of stents on which the valve structures are ordinarily mounted: a self-expanding stent and a balloon- expandable stent.
- the valve is generally first collapsed or crimped to reduce its circumferential size.
- the prosthetic valve When a collapsed prosthetic valve has reached the desired implant site in the patient (e.g., at or near the annulus of the patient's heart valve that is to be replaced by the prosthetic valve), the prosthetic valve can be deployed or released from the delivery apparatus and re-expanded to full operating size.
- the desired implant site in the patient e.g., at or near the annulus of the patient's heart valve that is to be replaced by the prosthetic valve
- the prosthetic valve can be deployed or released from the delivery apparatus and re-expanded to full operating size.
- balloon expandable valves this generally involves releasing the entire valve, assuring its proper location, and then expanding a balloon positioned within the valve stent.
- the stent automatically expands as the sheath covering the valve is withdrawn.
- a stent includes an inflow end, an outflow end, a body section extending from the outflow end toward the inflow end, and an anchoring section adjacent the inflow end having a first annular disc and a second annular disc.
- the stent may have a collapsed condition and an expanded condition.
- the first annular disc and the second annular disc may each extend radially outwardly from the body section when the stent is in the expanded condition.
- a stent includes an inflow end, an outflow end, a body section extending from the outflow end toward the inflow end, an anchoring section adjacent the inflow end; and a transition section between the body section and the anchoring section.
- the transition section may have a diameter that is smaller than diameters of the body section and the anchoring section.
- the stent may have a collapsed condition, an expanded condition, and a longitudinal axis.
- the anchoring section may extend radially outwardly from the longitudinal axis when the stent is in the expanded condition.
- FIG. 1 is a schematic cutaway representation of a human heart showing a transapical delivery approach
- FIG. 2 is a schematic representation of a native mitral valve and associated cardiac structures
- FIG. 3A is a bottom perspective view of a stent of a prosthetic heart valve according to an embodiment of the disclosure
- FIG. 3B is a schematic representation of the stent of FIG. 3A disposed in a native valve annul s;
- FIG. 4A is a front view of a front portion of a stent of a prosthetic heart valve according to another embodiment of the disclosure.
- FIG. 4B is a schematic, representation of the stent of FIG. 4A disposed in a native valve annulus
- FIG. 4C is a front, view of a front, portion of a stent of a prosthetic heart valve according to a further embodiment of the disclosure.
- inflow end when used in connection with a prosthetic atrioventricular heart valve, refers to the end of the heart valve closest to the atrium when the heart valve is implanted in a patient
- outlet flow end when used in connection with a prosthetic atrioventricular heart valve, refers to the end of the heart valve closest to the ventricle when, the heart valve is implanted in a patient.
- proximal and distal are to be taken as relative to a user using the device in an intended manner.
- Proximal is to be understood as relatively close to the user and “distal” is to be understood as relatively farther away from the user.
- distal is to be understood as relatively farther away from the user.
- the terms “substantially,” “generally,” and “about” are intended to mean that slight deviations from absolute are included within the scope of the term so modified.
- materials described as being suitable for components in one embodiment may also be suitable for similar components described in other embodiments.
- embodiments disclosed herein are generally described in relation to replacement of a native mitral valve, it should be understood that the disclosed embodiments and variants thereof may be suitable to replace other valves, including other heart valves such as the aortic or tricuspid valve. When ranges of values are described herein, those ranges are intended to include sub-ranges . For example, a recited range of 1 to 10 includes 2, 5, 7, and other single values, as well as ranges of 2 to 6, 3 to 9, 4 to 5, and others.
- FIG. 1 is a schematic cutaway representation of human heart 100,
- the human heart includes two atria and two ventricles: right atrium 112 and left atrium 122, and right ventricle 114 and left ventricle 124.
- Heart 100 further includes aorta 110, and aortic arch 120.
- mitral valve 130 Disposed between the left atrium and the left ventricle is mitral valve 130.
- Mitral valve 130 also known as the bicuspid valve or left atrioventricular valve, is a dual-flap that opens as a result of increased pressure in left atrium 122 as it fills with blood.
- mitral valve 130 opens and blood passes into left ventricle 124. Blood flows through heart 100 in the direction shown by arrows "B" .
- a dashed arrow, labeled "TA” indicates a transapical approach of implanting a prosthetic heart valve, in this case to replace the mitral valve.
- TA transapical delivery
- TS transseptal approach of implanting a prosthetic heart valve in which the valve is passed through the septum between right atrium 112 and left, atrium 122.
- Other approaches for implanting a prosthetic heart valve are also possible and may be used in connection with the disclosed embodiments .
- FIG. 2 is a more detailed schematic representation of native mitral valve 130 and its associated structures.
- mitral valve 130 includes two flaps or leaflets, posterior leaflet 136 and anterior leaflet 138, disposed between left atrium 122 and left ventricle 124, Cord-like tendons, known as chordae tendineae 134, connect the two leaflets 136, 138 to the medial and lateral papillary muscles 132.
- Atrial systole blood flows from higher pressure in left atrium 122 to lower pressure in left ventricle 124.
- left ventricle 124 contracts in ventricular systole
- the increased blood pressure in the chamber pushes leaflets 136, 138 to close, preventing the backflow of blood into left atrium 122.
- leaflets 136, 138 attempt to evert. to the low pressure regions, Chordae tendineae 134 prevent the eversion by becoming tense, thus pulling on leaflets 136, 1.38 and holding them in the closed position .
- valve When a. self-expanding prosthetic heart, valve is implanted in a. patient, for example at the an.nu.lus of a native heart valve, it generally is biased, towards an expanded condition, providing radial force to anchor the valve in place.
- This may be true of prosthetic heart valves used to replace the aortic valve as well as those used to replace the mitral valve.
- the radial force may anchor the prosthetic valve onto calcified native leaflets around the aortic root.
- anchoring with radial force may be more challenging.
- tissue in the left atrium adjacent the mitral valve to which a stent may anchor via radial force may be at least in part due to the fact that there is relatively little tissue in the left atrium adjacent the mitral valve to which a stent may anchor via radial force. This is also true of the area available in the right atrium adjacent the tricuspid valve. In contrast, there is a relatively large amount of solid tissue in the aorta adjacent the aortic valve available for anchoring a stent via radial force. For example, the aortic root, which is adjacent the aortic valve, may provide ample structure for anchoring a stent via radial force. In addition, if the radial force used to anchor a prosthetic heart valve is too high, damage may occur to heart tissue.
- the heart valve may move from its implanted position.
- a prosthetic mitral valve may migrate into left, ventricle 124 or left atrium 122 if the radial force is too low, requiring emergency surgery to remove the displaced valve.
- the potential for such movement may be heightened in mitral valve applications, particularly if a low profile valve is used,
- valves Another potential issue with prosthetic heart, valves is inadequate sealing between the prosthetic valve and the native tissue. For example, if a prosthetic heart valve is implanted at the annulus of mitral valve 130 in a patient, improper or inadequate sealing may result in blood flowing from left ventricle 124 into left atrium 122, even if the prosthetic leaflets of the valve assembly are working properly. This may occur, for example, if blood flows in a retrograde fashion between the outer perimeter of the prosthetic heart valve and the native tissue at the site of implantation. This phenomenon is known as perivalvular (or paravalvular) leak ("?V leak”) .
- FIG. 3A illustrates a stent 300 of a prosthetic heart valve according to one embodiment of the disclosure.
- Stent 300 may be collapsible and expandable for use in a prosthetic heart valve intended to replace the function of a native heart valve of a patient, such as the mitral valve (see native mitral valve 130 of FIGS . 1-2) .
- stent 300 is illustrated in an expanded condition.
- the remaining components that would be attached to stent 300 to form a prosthetic heart, valve, such as prosthetic valve leaflets and a cuff, are omitted from the figure for clarity.
- Stent 300 may be formed from biocompatible materials that are capable of self-expansion, such as, for example, shape memory alloys including Nitinol .
- stent 300 extends from inflow end 310 to outflow end 312.
- a plurality of struts 320 may form cells 322 in stent 300, the cells being connected to one another in one or more annular rows around the stent.
- Cells 322 may all be of substantially the same size around the perimeter and along the length of stent 300. However, ceils 322 nearer inflow end 310 may be larger or smaller than the cells nearer outflow end 312.
- Stent 300 may have a body or leaflet, section 330 extending from outflow end 312 toward inflow end 310.
- Leaflet section 330 may have a substantially cylindrical shape.
- prosthetic valve leaflets When used in a prosthetic heart valve, prosthetic valve leaflets may be attached directly or indirectly to an inner surface of leaflet section 330.
- Leaflet section 330 may take other shapes, such as a substantially conical shape or a general w D"-shape, which may better correspond to the shape of the native valve ann lus in which stent 300 is implanted.
- stent 300 may be provided with prosthetic, valve leaflets, One, two, or more prosthetic valve leaflets may be. included in a valve assembly attached to stent 300.
- the valve assembly may be substantially cylindrical, although other shapes may be suitable, and may include a cuff attached to leaflet section 330.
- the prosthetic leaflets maybe attached to the cuff or directly to struts 320 of leaflet section 330, When used to replace a mitral valve, the prosthetic leaflets replace the function of native mitral valve leaflets 136 and 138 described above in connection with FIG. 2. That is, the prosthetic leaflets coapt with one another to function as a one-way valve. It should be appreciated that a prosthetic heart valve incorporating stent.
- Both the cuff and leaflets may be wholly or partly formed of any suitable biological material, such as bovine or porcine pericardium, or polymers, such as polytetrafluoroethylene (PTFE) , urethanes and the like.
- the valve assembly may be secured to stent 300 by suturing to struts 320 or by using tissue glue, ultrasonic welding or other suitable methods.
- An anchoring or clamp section 340 may be positioned adjacent the leaflet section 330 and inflow end 310.
- Clamp section 340 may include a first disc 342 and a second disc 344.
- Each disc 342, 344 may be generally annular and may take the form of a mesh or braid, including metal braids such as braided Nitinol.
- Alternativel f first disc 342 and/or second disc 344 may be formed of fabrics and/or polymers, such as PTFE, urethanes, and the like.
- discs 342 and 344 may be formed of tissue, such as bovine or porcine cardiac tissue.
- discs 342 and 344 may each be formed of the same material, disc 342 may be formed of any one of the materials described above while disc 344 may be formed of a different material described above.
- Disc 342 may be attached to inflow end 310 by, for example, sutures, metal pressed clamping, adhesives, ultrasonic welding, or other suitable methods.
- Disc 344 may be attached to disc 342 by any suitable method.
- discs 342 and 344 may be formed as a single unit from the same material.
- discs 342 and 344 When discs 342 and 344 are both formed of the same material as stent 300, discs 342 and 344 may be formed as a single unit with the remainder of stent 300. Preferably, clamp section 340 is positioned in series with leaflet section 330. In other words, neither disc 342 nor disc 344 overlap struts 320 of stent 300 when the stent is in the collapsed condition. When in the expanded condition, there is no overlap or minimal overlap between the discs 342, 344 and the struts 320. As described in more detail below, this may help reduce the profile of stent 300 during delivery.
- First disc 342 may be positioned closer to outflow end 312 than second disc 344, which ma be positioned farther- away from outflow end 312,
- the diameter of first disc 342 may be smaller than the diameter of second disc 344,
- second disc 344 may extend farther radially outwardly from a longitudinal axis LI of stent 300.
- stent. 300 may be implanted in a native mitral, valve annulus VA with first disc 342 positioned, within left ventricle 124 and second disc 344 positioned, within left atrium 122, as illustrated in FIG. 33.
- second disc 344 on the atrial side of native valve annulus VA helps anchor stent 300 in place, resisting migration into left ventricle 124.
- first disc 342 on the ventricular side of native valve annulus VA helps resist migration of stent. 300 into left atrium 122.
- the relatively large size of second disc 344 compared to first disc 342 may be useful in that there may be a greater anatomical area available for contact on the atrial side of native valve annulus VA.
- stent 300 may rely less on radial anchoring force and thus avoid some or all of the potential issues described above in connection with the use of radial force to anchor a prosthetic heart valve within a native valve annulus.
- first disc 342 may be shape-set, for example by heat setting, such that it flares or is biased away from outflow end 312,
- second disc 344 may be shape-set such that it. flares or is biased toward outflow end 312,
- first disc 342 and second disc 344 may act together to pinch native valve annulus VA, Such biasing, however, is not required.
- one or both of first disc 342 and second disc 344 may extend at. an angle of about 90 degrees from the longitudinal axis LILi of stent 300 when stent 300 is in the relaxed or expanded condition. It should be understood that other angles or ranges of angles from longitudinal axis LI, for example between about 60 degrees and about 120 degrees, between about 70 degrees and about. 110 degrees, or between about 80 degrees and about. 100 degrees, may also be suitable,
- first disc 342 and second disc 344 may provide a relatively large surface area with which the native anatomy may interact and into which tissue can grow, helping secure stent 300 further. This may result in both better anchoring and better sealing of the prosthetic heart valve incorporating stent 300. Additionally, sealing may be further improved by providing a fabric or other covering over first disc 342 and second disc 344, which may enhance tissue ingrowth and healing. In certain arrangements, such fabric or other covering ma be applied only to first disc 342 or only to second disc 344.
- first disc 342 and second disc 344 may be part of a single continuous mesh or braided structure, with the discs being at. substantially opposite ends of the braided structure. .However, each disc may be provided independently of the other. Whether separate structures or part of one continuous structure, a space between first disc 342 and second disc 344 defines an annuius gap 370 in which the native valve annuius VA is positioned when stent 300 is implanted. Having the first disc 342 and the second disc 344 on opposite ends of an an nuisanceus gap helps anchor stent 300 in the native valve annuius VA, and further may help restrict movement of native valve leaflets that may- still be partially or fully intact.
- stent 300 When being used in a prosthetic heart valve for replacing the native mitral valve of a patient, stent 300 is crimped to a collapsed condition and positioned within, a catheter or similar structure of a delivery device.
- the delivery device may, for example, be inserted through the apex of the heart (transapical delivery! or through the femoral artery and passed through the vasculature to the implant site ( trans femoral delivery) , although other delivery routes may be used. If a transapical method is used, retaining tabs 360 on outflow end 312 of stent 300 may be connected to the delivery device and may be configured to maintain a connection between stent 300 and the delivery device prior to full release of the stent.
- clamp section 340 When stent 300 is crimped and in the collapsed condition, clamp section 340 extends away from leaflet section 330, Once the delivery device is near the site of implantation, the sheath or other member compressing stent 3C0 may be slowly retracted to reveal stent 300 and allow it to expand to the expanded condition. As the sheath is retracted, clamp section 340 may begin to expand, prior to leaflet section 330, such that the proper positioning of first disc 342 and second disc 344 relative to the native valve annuins VA may be confirmed before continuing release of the stent. Once confirmed, retraction of the sheath may be continued to allow leaflet section 330, along with the valve assembly with prosthetic leaflets positioned therein, to expand into the implantation site.
- the sheath may be further retracted to release retaining tabs 360 to fully release stent 300 into the patient. If the positioning is not acceptable, the sheath may be advanced in the opposite direction to partially or completely resheathe stent 300. Once partially or fully resheathed, the user may attempt to properly position and release stent 300 again, Similarly, when using other delivery routes, such as a trans septal route, retaining tabs may be formed near inflow end 310 with the outflow end 312 being expanded first. Further, as shown in FIG. 3B, the valve 300 may be implanted such that leaflet section 330 is substantially or fully in a supraannular position. When used in the context of an atrioventricular valve, supraannular refers to a position closer to a position beyond the native valve annulus in the direction of the ventricle.
- the size of the prosthetic heart valve in the collapsed condition may be an important, factor.
- a prosthetic heart valve that retains a large profile in the collapsed condition will need to be delivered using a delivery device with a correspondingly large catheter.
- a prosthetic hear valve with a small, profile in the collapsed condition may be implanted using a delivery device with a correspondingly small catheter. If first disc 342 and/or second disc 344 were positioned along a portion of leaflet section 330, stent 300 would have a relatively large crimp profile and require a relatively large catheter.
- clamp section 340 and leaflet section 330 are positioned in series such that, when crimped and loaded into a delivery device in the collapsed condition, most or all of first disc 342 and second disc 342 do not overlap with struts 320 of leaflet section 330. Avoiding this overlap facilitates a reduction in crimp profile, thus allowing relatively small catheters to be used to deliver and implant prosthetic heart valves incorporating stent 300.
- FIG. 4A illustrates a stent 400 of a prosthetic heart valve according to another embodiment, of the disclosure
- Stent 400 may have features similar to stent 300.
- stent 400 may be collapsible and expandable for use in a prosthetic heart valve intended to replace the function of a native heart valve of a patient.
- Stent 400 is illust ated in FIG. 4A in an expanded condition, omitting the back side of the stent for clarity, and omitting other components that could be attached to the stent to form a prosthetic heart valve, such as prosthetic valve leaflets and a cuff.
- Stent 400 may be formed from, biocompatible materials that are capable of self-expansion, including Nitinol or super-elastic polymeric materials.
- An inflow end 410 may be positioned on the opposite end of stent 400 than an outflow end 412.
- a plurality of struts 420 may form cells 422 connected to one another in one or more annular rows around the stent.
- cells 422 of stent 400 may all be of substantially the same size around the perimeter and along the length of stent 400 or cells 422 nearer inflow end 410 may be larger or smaller than the cells nearer outflow end 412.
- a prosthetic, heart valve incorporating stent 400 may include prosthetic valve leaflets, such as these described above in connection with the embodiment of FIGS. 3A-B.
- the prosthetic valve leaflets may be. attached to stent 400 at. a body or leaflet, section 430, which may extend from outflow end 412 toward inflow end 410,
- Leaflet section 430 may have a substantiall cylindrical shape as illustrated in FIG. A, but may take other shapes.
- leaflet section 430 is positioned closer to outflow end 412 of stent 400
- an anchor or flange section 440 is positioned adjacent inflow section 410.
- Flange section 440 may be integral with the remainder of stent 400 and. may be defined at least in part by a plurality of cells 422 and/or struts 420 extending radially outwardly.
- the stent 400, including flange section 440 may be formed by laser cutting a single tube of material into the desired shape, although other methods of manufacture may be suitable.
- the cells 422 and/or struts 420 defining flange section 440 may be configured to extend at an angle of about 90 degrees from a longitudinal axis L2 of stent 400 when stent 400 is in the relaxed or expanded condition. It should be understood that other angles or ranges of angles, for example between about 60 degrees and about 120 degrees, between about 70 degrees and about 110 degrees, or between about 80 degrees and about 100 degrees, may also be suitable. It should further be noted that flange section 440 need not be integral with the remainder of stent 400, and may be attached to leaflet section 430 and formed of materials other than Nitinol. Flange section 440 transitions to leaflet section 430 via a reduced diameter transition section, referred to herein as annuius groove 470.
- the diameter Dl of stent 400 at the innermost portion of an nuisance groove 470 is smaller than the diameter of the flange section 440 and the diameter D2 of leaflet section 430.
- the diameter Dl of annuius groove 470 at the innermost portion is equal to or smaller than the diameter of native valve an nuisanceus VA, while diameter D2 is preferably larger than the inner diameter of the native valve annuius. This arrangement may facilitate better securement of stent 400 in the native anatomy, including the an nuisanceus and portions of native leaflets .
- a prosthetic, heart valve incorporating stent 400 may be positioned within a native valve annuius VA as illustrated in FIG. 43, which omits from the illustration components of the prosthetic heart valve other than stent 400.
- flange section 440 When implanted, flange section 440 may be positioned in left atrium 122. The elastic properties of the struts forming flange section 440 and the above-described shape setting helps flange section 440 conform to the atrial surface of native valve annuius VA .
- anakius groove 470 is positioned adjacent native valve an nuisance VA, such that, the sidewalls of an nuisance groove 470 perform a clamp-like function.
- the annuius groove 470 in combination with the diameter D2 of leaflet section 430 being larger than the diameter of the native valve annulus VA, helps the valve resist slipping into left atrium 122.
- FIGS. 4A-B omit certain structures which may be used in addition to stent 400 to form a prosthetic heart valve.
- one or more cuffs may be attached on flange section 430 and/or at annulus groove 470 to help prevent PV leak.
- the number of prosthetic leaflets within the leaflet section 430 may be one, two, three, or more.
- the cuffs and prosthetic leaflets may be formed of the same or similar materials as described above in connection with the embodiment of FIGS, 3.A---B.
- stent 400 When being used in a. prosthetic heart, valve for replacing the native mitral valve of a patient, stent 400 is crimped to a. collapsed condition and positioned within a catheter or similar structure of a delivery device prior to implantation.
- the method of delive ing a prosthetic heart valve incorporating stent 400 may be substantially similar to that described in connection with stent 300 of FIGS. 3A-B .
- retaining tabs 460 on inflow end 410 of stent 400 may be connected to the delivery device to couple stent 400 to the delivery device until stent 400 is fully expanded.
- Retaining tabs may be formed on outflow end 412 of stent 400, on the other hand, for retaining stent 400 in a delivery device during a transapica.1 delivery. Further, the valve 400 may be implanted such that leaflet section 430 is substantially or fully in a supraarmular position.
- leaflet section 430 is illustrated with a substantially cylindrical shape in FIG. 4A, other shapes are possible.
- leaflet body 430' is illustrated in FIG. 4C as having a barrel shape.
- barrel-shaped leaflet section 430' has a circumference that is larger (i.e., projects farther radially outward) in a center portion than it is on either side of the center portion.
- the barrel-shaped body may reduce the interference of stent 400' with heart structures within a native ventricle.
- leaflet section 430 may also be generally w D"-shaped to better conform to native annulus VA. For example, interference may be reduced in the sense that the relatively smooth barrel shape is less likely to "poke" or otherwise detrimentally engage with chordae tendinae or native leaflets.
- stents and prosthetic heart valves are generally described for replacement of the mitral other bicuspid valves, variations may be made to these devices to replace tricuspid valves.
- the prosthetic valves may be provided with three leaflets, or more or fewer leaflets as desired.
- the principles described herein are also applicable to prosthetic valves that, are not self-expanding, such as balloon-expandable prosthetic valves ,
- a stent has a collapsed, condition and an expanded condition, the stent comprising a body having an outflow end and an inflow end; and an anchoring section adjacent the inflow end and including a first annular disc and a second annular disc, the first, annular disc and the second annular disc each extending radially outwardly from the body when the stent is i the expanded condition; and/or
- the first disc has a smaller diameter than the second disc when the stent is in the expanded, condition
- the second disc is positioned farther away from the outflow end than the first disc; and/or the first disc and the second disc are eac formed of a braided material; and/or
- the braided material is itinol; and/or
- the anchoring section includes a gap between the first disc and the second disc when the stent is in the expanded condition
- the first disc is integral with the second disc; and/or the first disc and the second disc are each integral with he body ; and/or
- the first disc flares away from the outflow end and the second disc flares toward the outflow end when the stent is in the expanded condition;
- the first disc and the second disc each extend at an angle of about 90 degrees from a longitudinal axis of the body when the stent is in. the expanded condition;
- a prosthetic heart, valve having at least two prosthetic heart valve leaflets positioned, within the body.
- a stent has a collapsed conditio and an expanded condition, the stent comprising a body having a longitudinal axis, an outflow end, an inflow end, and a diameter in the expanded condition of the stent; an anchoring section adjacent the inflow end, and the anchoring section having a diameter in the expanded condition of the stent; and a transition section between the body and the anchoring section, the transition section in the expanded condition of the stent having a diameter that is smaller than the diameter of the body and smaller than the diameter of the anchoring section, wherein the anchoring section extends radially outwardly from the longitudinal axis of the body when the stent is in the expanded condition; and/or
- the anchoring section includes a plurality of struts forming cells;
- the anchoring section is integral with the body; and/or the anchoring section extends radially outwardly from the longitudinal axis of the body at an angle of between about. 80 degrees and about 100 degrees when the stent is in the expanded condition; and/or
- the anchoring section extends radially outwardly from the longitudinal axis of the body at an angle of about 90 degrees when the stent is in the expanded condition;
- the body is substantially cylindrical; and/or
- the body has a center portion between the inflow end and the outflow end, the center portion having a circumference that is larger than a circumference of the body on either side of the center portion when the stent is in the expanded condition;
- a prosthetic heart valve having at least two prosthetic heart valve leaflets positioned within the body.
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Cardiology (AREA)
- Oral & Maxillofacial Surgery (AREA)
- Transplantation (AREA)
- Heart & Thoracic Surgery (AREA)
- Vascular Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Prostheses (AREA)
Abstract
A stent (300, 400, 400') for a prosthetic heart valve includes a body having an inflow end (310, 410) and an outflow end (312, 412), and an anchoring section (340, 440) adjacent the inflow end. The anchoring section may include structure (342, 344, 420) that extends radially outwardly from the body when the stent is in an expanded condition. The stent may include a transition section (370, 470) between the body and the anchoring section, the transition section in the expanded condition of the stent having a diameter that is smaller than the diameters of the body and the anchoring section. When implanted into a native valve annulus, such as the mitral valve annulus, the anchoring section may help the stent resist migrating away from the native valve annulus.
Description
STENTS WITH ANCHORING SECTIONS
CROSS-REFERENCE TO RELATED APPLICATIONS
[0001] The present application claims the benefit of the filing date of U.S. Provisional Application No, 62/001,793, filed May 22, 2014, entitled "STENT WITH ANCHORING SECTIONS," the disclosure of which is hereby incorporated by reference herein .
BACKGROUND
[0002] The. present disclosure relates to heart valve replacement and, in particular, to collapsible prosthetic heart valves. More particularly, the present disclosure relates to prosthetic heart valves that facilitate secure positioning within a native valve annulus .
[0003] Prosthetic heart, valves that are collapsible to a relatively small circumferential size can be delivered into a patient less invasively than valves that are not. collapsible. For example, a collapsible valve may be delivered into a patient via a tube-like delivery apparatus such as a catheter, a trocar, a laparoscopic instrument, or the like. This collapsibility can avoid the need for a more invasive procedure such as full open chest, open heart surgery.
[0004] Collapsible prosthetic heart valves typically take the form of a valve structure mounted on a stent. There are two types of stents on which the valve structures are ordinarily mounted: a self-expanding stent and a balloon- expandable stent. To place such valves into a delivery- apparatus and ultimately into a patient, the valve is generally first collapsed or crimped to reduce its circumferential size.
[0005] When a collapsed prosthetic valve has reached the desired implant site in the patient (e.g., at or near the annulus of the patient's heart valve that is to be replaced by the prosthetic valve), the prosthetic valve can be deployed or
released from the delivery apparatus and re-expanded to full operating size. For balloon expandable valves, this generally involves releasing the entire valve, assuring its proper location, and then expanding a balloon positioned within the valve stent. For self-expanding valves, on the other hand, the stent automatically expands as the sheath covering the valve is withdrawn.
BRIEF SUMMARY
[0006] According to one embodiment of the disclosure, a stent includes an inflow end, an outflow end, a body section extending from the outflow end toward the inflow end, and an anchoring section adjacent the inflow end having a first annular disc and a second annular disc. The stent may have a collapsed condition and an expanded condition. The first annular disc and the second annular disc may each extend radially outwardly from the body section when the stent is in the expanded condition.
[0007] According to another embodiment of the disclosure, a stent includes an inflow end, an outflow end, a body section extending from the outflow end toward the inflow end, an anchoring section adjacent the inflow end; and a transition section between the body section and the anchoring section. The transition section may have a diameter that is smaller than diameters of the body section and the anchoring section. The stent. may have a collapsed condition, an expanded condition, and a longitudinal axis. The anchoring section may extend radially outwardly from the longitudinal axis when the stent is in the expanded condition.
BRIEF DESCRIPTION OF THE DRAWINGS
[0008] Various embodiments of the present disclosure are described herein with reference to the drawings, wherein:
[0009] FIG, 1 is a schematic cutaway representation of a human heart showing a transapical delivery approach;
[0010] FIG. 2 is a schematic representation of a native mitral valve and associated cardiac structures;
[0011] FIG. 3A is a bottom perspective view of a stent of a prosthetic heart valve according to an embodiment of the disclosure;
[0012] FIG. 3B is a schematic representation of the stent of FIG. 3A disposed in a native valve annul s;
[0013] FIG. 4A is a front view of a front portion of a stent of a prosthetic heart valve according to another embodiment of the disclosure;
[0014] FIG. 4B is a schematic, representation of the stent of FIG. 4A disposed in a native valve annulus; and
[0015] FIG. 4C is a front, view of a front, portion of a stent of a prosthetic heart valve according to a further embodiment of the disclosure.
[0016] Various embodiments of the present disclosure will now be described with reference to the appended drawings . It is to be appreciated that these drawings depict only some embodiments of the disclosure and are therefore not to be considered limiting of its scope.
DETAILED DESCRIPTION
[0017] Blood flows through the mitral valve from the left atrium to the left ventricle. As used herein, the term, "inflow end, " when used in connection with a prosthetic atrioventricular heart valve, refers to the end of the heart valve closest to the atrium when the heart valve is implanted in a patient, whereas the term "outflow end," when used in connection with a prosthetic atrioventricular heart valve, refers to the end of the heart valve closest to the ventricle when, the heart valve is implanted in a patient. Further, when used herein with reference to a delivery device, the terms "proximal" and "distal" are to be taken as relative to a user using the device in an intended manner. "Proximal" is to be
understood as relatively close to the user and "distal" is to be understood as relatively farther away from the user. Also, as used herein, the terms "substantially," "generally," and "about" are intended to mean that slight deviations from absolute are included within the scope of the term so modified. Generally, materials described as being suitable for components in one embodiment may also be suitable for similar components described in other embodiments. Although embodiments disclosed herein are generally described in relation to replacement of a native mitral valve, it should be understood that the disclosed embodiments and variants thereof may be suitable to replace other valves, including other heart valves such as the aortic or tricuspid valve. When ranges of values are described herein, those ranges are intended to include sub-ranges . For example, a recited range of 1 to 10 includes 2, 5, 7, and other single values, as well as ranges of 2 to 6, 3 to 9, 4 to 5, and others.
[0018] FIG. 1 is a schematic cutaway representation of human heart 100, The human heart includes two atria and two ventricles: right atrium 112 and left atrium 122, and right ventricle 114 and left ventricle 124. Heart 100 further includes aorta 110, and aortic arch 120. Disposed between the left atrium and the left ventricle is mitral valve 130. Mitral valve 130, also known as the bicuspid valve or left atrioventricular valve, is a dual-flap that opens as a result of increased pressure in left atrium 122 as it fills with blood. As atrial pressure increases above that of left ventricle 124, mitral valve 130 opens and blood passes into left ventricle 124. Blood flows through heart 100 in the direction shown by arrows "B" .
[0019] A dashed arrow, labeled "TA" , indicates a transapical approach of implanting a prosthetic heart valve, in this case to replace the mitral valve. In transapical
delivery, a small incision is made between the ribs and into the apex of left ventricle 124 to deliver the prosthetic heart valve to the target site. A second dashed arrow, labeled "TS", indicates a transseptal approach of implanting a prosthetic heart valve in which the valve is passed through the septum between right atrium 112 and left, atrium 122. Other approaches for implanting a prosthetic heart valve are also possible and may be used in connection with the disclosed embodiments .
[0020] FIG. 2 is a more detailed schematic representation of native mitral valve 130 and its associated structures. As previously noted, mitral valve 130 includes two flaps or leaflets, posterior leaflet 136 and anterior leaflet 138, disposed between left atrium 122 and left ventricle 124, Cord-like tendons, known as chordae tendineae 134, connect the two leaflets 136, 138 to the medial and lateral papillary muscles 132. During atrial systole, blood flows from higher pressure in left atrium 122 to lower pressure in left ventricle 124, When left ventricle 124 contracts in ventricular systole, the increased blood pressure in the chamber pushes leaflets 136, 138 to close, preventing the backflow of blood into left atrium 122, Since the blood pressure in left atrium 122 is much lower at this point in a heartbeat than that in left ventricle 124, leaflets 136, 138 attempt to evert. to the low pressure regions, Chordae tendineae 134 prevent the eversion by becoming tense, thus pulling on leaflets 136, 1.38 and holding them in the closed position .
[0021] When a. self-expanding prosthetic heart, valve is implanted in a. patient, for example at the an.nu.lus of a native heart valve, it generally is biased, towards an expanded condition, providing radial force to anchor the valve in place. This may be true of prosthetic heart valves used to
replace the aortic valve as well as those used to replace the mitral valve. When replacing the aortic valve, the radial force may anchor the prosthetic valve onto calcified native leaflets around the aortic root. When replacing the left, atrioventricular valve (known as the mitral or bicuspid valve) or the right atrioventricular valve (known as the tricuspid valve) , anchoring with radial force may be more challenging. This may be at least in part due to the fact that there is relatively little tissue in the left atrium adjacent the mitral valve to which a stent may anchor via radial force. This is also true of the area available in the right atrium adjacent the tricuspid valve. In contrast, there is a relatively large amount of solid tissue in the aorta adjacent the aortic valve available for anchoring a stent via radial force. For example, the aortic root, which is adjacent the aortic valve, may provide ample structure for anchoring a stent via radial force. In addition, if the radial force used to anchor a prosthetic heart valve is too high, damage may occur to heart tissue. If, instead, the radial force is too low, the heart valve may move from its implanted position. For example, a prosthetic mitral valve may migrate into left, ventricle 124 or left atrium 122 if the radial force is too low, requiring emergency surgery to remove the displaced valve. The potential for such movement, may be heightened in mitral valve applications, particularly if a low profile valve is used,
[0022] Another potential issue with prosthetic heart, valves is inadequate sealing between the prosthetic valve and the native tissue. For example, if a prosthetic heart valve is implanted at the annulus of mitral valve 130 in a patient, improper or inadequate sealing may result in blood flowing from left ventricle 124 into left atrium 122, even if the prosthetic leaflets of the valve assembly are working
properly. This may occur, for example, if blood flows in a retrograde fashion between the outer perimeter of the prosthetic heart valve and the native tissue at the site of implantation. This phenomenon is known as perivalvular (or paravalvular) leak ("?V leak") .
[0023] FIG. 3A illustrates a stent 300 of a prosthetic heart valve according to one embodiment of the disclosure. Stent 300 may be collapsible and expandable for use in a prosthetic heart valve intended to replace the function of a native heart valve of a patient, such as the mitral valve (see native mitral valve 130 of FIGS . 1-2) . In FIG. 3A, stent 300 is illustrated in an expanded condition. The remaining components that would be attached to stent 300 to form a prosthetic heart, valve, such as prosthetic valve leaflets and a cuff, are omitted from the figure for clarity.
[0024] Stent 300 may be formed from biocompatible materials that are capable of self-expansion, such as, for example, shape memory alloys including Nitinol . Generally, stent 300 extends from inflow end 310 to outflow end 312. A plurality of struts 320 may form cells 322 in stent 300, the cells being connected to one another in one or more annular rows around the stent. Cells 322 may all be of substantially the same size around the perimeter and along the length of stent 300. However, ceils 322 nearer inflow end 310 may be larger or smaller than the cells nearer outflow end 312.
[0025] Stent 300 may have a body or leaflet, section 330 extending from outflow end 312 toward inflow end 310. Leaflet section 330 may have a substantially cylindrical shape. When used in a prosthetic heart valve, prosthetic valve leaflets may be attached directly or indirectly to an inner surface of leaflet section 330. Leaflet section 330 may take other shapes, such as a substantially conical shape or a general
wD"-shape, which may better correspond to the shape of the native valve ann lus in which stent 300 is implanted.
[0026] As noted above, stent 300 may be provided with prosthetic, valve leaflets, One, two, or more prosthetic valve leaflets may be. included in a valve assembly attached to stent 300. The valve assembly may be substantially cylindrical, although other shapes may be suitable, and may include a cuff attached to leaflet section 330. The prosthetic leaflets maybe attached to the cuff or directly to struts 320 of leaflet section 330, When used to replace a mitral valve, the prosthetic leaflets replace the function of native mitral valve leaflets 136 and 138 described above in connection with FIG. 2. That is, the prosthetic leaflets coapt with one another to function as a one-way valve. It should be appreciated that a prosthetic heart valve incorporating stent. 300 may have more than two prosthetic leaflets when used to replace the mitral valve or other cardiac valves within a patient. Both the cuff and leaflets may be wholly or partly formed of any suitable biological material, such as bovine or porcine pericardium, or polymers, such as polytetrafluoroethylene (PTFE) , urethanes and the like. The valve assembly may be secured to stent 300 by suturing to struts 320 or by using tissue glue, ultrasonic welding or other suitable methods.
[0027] An anchoring or clamp section 340 may be positioned adjacent the leaflet section 330 and inflow end 310. Clamp section 340 may include a first disc 342 and a second disc 344. Each disc 342, 344 may be generally annular and may take the form of a mesh or braid, including metal braids such as braided Nitinol. Alternativel f first disc 342 and/or second disc 344 may be formed of fabrics and/or polymers, such as PTFE, urethanes, and the like. In still other embodiments, discs 342 and 344 may be formed of tissue, such as bovine or
porcine cardiac tissue. Some or all of the above materials may be used in combination with a coating, such as a collagen coating, a fibrin coating, or a polymer coating (such as a silicone coating) . In addition, while discs 342 and 344 may each be formed of the same material, disc 342 may be formed of any one of the materials described above while disc 344 may be formed of a different material described above. Disc 342 may be attached to inflow end 310 by, for example, sutures, metal pressed clamping, adhesives, ultrasonic welding, or other suitable methods. Disc 344 may be attached to disc 342 by any suitable method. Alternatively, discs 342 and 344 may be formed as a single unit from the same material. When discs 342 and 344 are both formed of the same material as stent 300, discs 342 and 344 may be formed as a single unit with the remainder of stent 300. Preferably, clamp section 340 is positioned in series with leaflet section 330. In other words, neither disc 342 nor disc 344 overlap struts 320 of stent 300 when the stent is in the collapsed condition. When in the expanded condition, there is no overlap or minimal overlap between the discs 342, 344 and the struts 320. As described in more detail below, this may help reduce the profile of stent 300 during delivery.
[0028] First disc 342 may be positioned closer to outflow end 312 than second disc 344, which ma be positioned farther- away from outflow end 312, The diameter of first disc 342 may be smaller than the diameter of second disc 344, In other words, second disc 344 may extend farther radially outwardly from a longitudinal axis LI of stent 300. With this configuration, stent. 300 may be implanted in a native mitral, valve annulus VA with first disc 342 positioned, within left ventricle 124 and second disc 344 positioned, within left atrium 122, as illustrated in FIG. 33.
[0029] When positioned in the native mitral valve annulus VA, second disc 344 on the atrial side of native valve annulus VA helps anchor stent 300 in place, resisting migration into left ventricle 124. Similarly, first disc 342 on the ventricular side of native valve annulus VA helps resist migration of stent. 300 into left atrium 122, The relatively large size of second disc 344 compared to first disc 342 may be useful in that there may be a greater anatomical area available for contact on the atrial side of native valve annulus VA. As a result, stent 300 may rely less on radial anchoring force and thus avoid some or all of the potential issues described above in connection with the use of radial force to anchor a prosthetic heart valve within a native valve annulus. If formed of a material that may be shape-set, first disc 342 may be shape-set, for example by heat setting, such that it flares or is biased away from outflow end 312, Similarly, second disc 344 may be shape-set such that it. flares or is biased toward outflow end 312, In this configuration, first disc 342 and second disc 344 may act together to pinch native valve annulus VA, Such biasing, however, is not required. Thus, in other embodiments,, one or both of first disc 342 and second disc 344 may extend at. an angle of about 90 degrees from the longitudinal axis LILi of stent 300 when stent 300 is in the relaxed or expanded condition. It should be understood that other angles or ranges of angles from longitudinal axis LI, for example between about 60 degrees and about 120 degrees, between about 70 degrees and about. 110 degrees, or between about 80 degrees and about. 100 degrees, may also be suitable,
[0030] The use of a mesh or braided wire to form first disc 342 and second disc 344 may provide a relatively large surface area with which the native anatomy may interact and into which tissue can grow, helping secure stent 300 further. This may
result in both better anchoring and better sealing of the prosthetic heart valve incorporating stent 300. Additionally, sealing may be further improved by providing a fabric or other covering over first disc 342 and second disc 344, which may enhance tissue ingrowth and healing. In certain arrangements, such fabric or other covering ma be applied only to first disc 342 or only to second disc 344.
[0031] As illustrated in FIGS. 3B, first disc 342 and second disc 344 may be part of a single continuous mesh or braided structure, with the discs being at. substantially opposite ends of the braided structure. .However, each disc may be provided independently of the other. Whether separate structures or part of one continuous structure, a space between first disc 342 and second disc 344 defines an annuius gap 370 in which the native valve annuius VA is positioned when stent 300 is implanted. Having the first disc 342 and the second disc 344 on opposite ends of an annuius gap helps anchor stent 300 in the native valve annuius VA, and further may help restrict movement of native valve leaflets that may- still be partially or fully intact.
[0032] When being used in a prosthetic heart valve for replacing the native mitral valve of a patient, stent 300 is crimped to a collapsed condition and positioned within, a catheter or similar structure of a delivery device. The delivery device may, for example, be inserted through the apex of the heart (transapical delivery! or through the femoral artery and passed through the vasculature to the implant site ( trans femoral delivery) , although other delivery routes may be used. If a transapical method is used, retaining tabs 360 on outflow end 312 of stent 300 may be connected to the delivery device and may be configured to maintain a connection between stent 300 and the delivery device prior to full release of the stent. When stent 300 is crimped and in the collapsed
condition, clamp section 340 extends away from leaflet section 330, Once the delivery device is near the site of implantation, the sheath or other member compressing stent 3C0 may be slowly retracted to reveal stent 300 and allow it to expand to the expanded condition. As the sheath is retracted, clamp section 340 may begin to expand, prior to leaflet section 330, such that the proper positioning of first disc 342 and second disc 344 relative to the native valve annuins VA may be confirmed before continuing release of the stent. Once confirmed, retraction of the sheath may be continued to allow leaflet section 330, along with the valve assembly with prosthetic leaflets positioned therein, to expand into the implantation site. If the positioning is acceptable to the user, the sheath may be further retracted to release retaining tabs 360 to fully release stent 300 into the patient. If the positioning is not acceptable, the sheath may be advanced in the opposite direction to partially or completely resheathe stent 300. Once partially or fully resheathed, the user may attempt to properly position and release stent 300 again, Similarly, when using other delivery routes, such as a trans septal route, retaining tabs may be formed near inflow end 310 with the outflow end 312 being expanded first. Further, as shown in FIG. 3B, the valve 300 may be implanted such that leaflet section 330 is substantially or fully in a supraannular position. When used in the context of an atrioventricular valve, supraannular refers to a position closer to a position beyond the native valve annulus in the direction of the ventricle.
[0033] When implanting a collapsible prosthetic heart, valve, the size of the prosthetic heart valve in the collapsed condition, including stent 300, may be an important, factor. For example, a prosthetic heart valve that retains a large profile in the collapsed condition will need to be delivered
using a delivery device with a correspondingly large catheter. On the other hand, a prosthetic hear valve with a small, profile in the collapsed condition may be implanted using a delivery device with a correspondingly small catheter. If first disc 342 and/or second disc 344 were positioned along a portion of leaflet section 330, stent 300 would have a relatively large crimp profile and require a relatively large catheter. In the illustrated embodiment, clamp section 340 and leaflet section 330 are positioned in series such that, when crimped and loaded into a delivery device in the collapsed condition, most or all of first disc 342 and second disc 342 do not overlap with struts 320 of leaflet section 330. Avoiding this overlap facilitates a reduction in crimp profile, thus allowing relatively small catheters to be used to deliver and implant prosthetic heart valves incorporating stent 300.
[0034] FIG. 4A illustrates a stent 400 of a prosthetic heart valve according to another embodiment, of the disclosure, Stent 400 may have features similar to stent 300. For example, stent 400 may be collapsible and expandable for use in a prosthetic heart valve intended to replace the function of a native heart valve of a patient. Stent 400 is illust ated in FIG. 4A in an expanded condition, omitting the back side of the stent for clarity, and omitting other components that could be attached to the stent to form a prosthetic heart valve, such as prosthetic valve leaflets and a cuff.
[0035] Stent 400 may be formed from, biocompatible materials that are capable of self-expansion, including Nitinol or super-elastic polymeric materials. An inflow end 410 may be positioned on the opposite end of stent 400 than an outflow end 412. A plurality of struts 420 may form cells 422 connected to one another in one or more annular rows around
the stent. As with stent 300, cells 422 of stent 400 may all be of substantially the same size around the perimeter and along the length of stent 400 or cells 422 nearer inflow end 410 may be larger or smaller than the cells nearer outflow end 412.
[0036] A prosthetic, heart valve incorporating stent 400 may include prosthetic valve leaflets, such as these described above in connection with the embodiment of FIGS. 3A-B. The prosthetic valve leaflets may be. attached to stent 400 at. a body or leaflet, section 430, which may extend from outflow end 412 toward inflow end 410, Leaflet section 430 may have a substantiall cylindrical shape as illustrated in FIG. A, but may take other shapes.
[0037] While leaflet section 430 is positioned closer to outflow end 412 of stent 400, an anchor or flange section 440 is positioned adjacent inflow section 410. Flange section 440 may be integral with the remainder of stent 400 and. may be defined at least in part by a plurality of cells 422 and/or struts 420 extending radially outwardly. The stent 400, including flange section 440, may be formed by laser cutting a single tube of material into the desired shape, although other methods of manufacture may be suitable. The cells 422 and/or struts 420 defining flange section 440 may be configured to extend at an angle of about 90 degrees from a longitudinal axis L2 of stent 400 when stent 400 is in the relaxed or expanded condition. It should be understood that other angles or ranges of angles, for example between about 60 degrees and about 120 degrees, between about 70 degrees and about 110 degrees, or between about 80 degrees and about 100 degrees, may also be suitable. It should further be noted that flange section 440 need not be integral with the remainder of stent 400, and may be attached to leaflet section 430 and formed of materials other than Nitinol. Flange section 440 transitions
to leaflet section 430 via a reduced diameter transition section, referred to herein as annuius groove 470. When in the relaxed or expanded condition, the diameter Dl of stent 400 at the innermost portion of annuius groove 470 is smaller than the diameter of the flange section 440 and the diameter D2 of leaflet section 430. Preferably, when implanted, the diameter Dl of annuius groove 470 at the innermost portion is equal to or smaller than the diameter of native valve annuius VA, while diameter D2 is preferably larger than the inner diameter of the native valve annuius. This arrangement may facilitate better securement of stent 400 in the native anatomy, including the annuius and portions of native leaflets .
[0038] In use, a prosthetic, heart valve incorporating stent 400 may be positioned within a native valve annuius VA as illustrated in FIG. 43, which omits from the illustration components of the prosthetic heart valve other than stent 400. When implanted, flange section 440 may be positioned in left atrium 122. The elastic properties of the struts forming flange section 440 and the above-described shape setting helps flange section 440 conform to the atrial surface of native valve annuius VA . During atrial systole when the prosthetic leaflets open, the forward force from left atrium 122 toward left ventricle 124 is relatively small and flange section 440 helps prevent the prosthetic heart valve incorporating stent 400 from slipping into left ventricle 124. Further, the innermost portion of annuius groove 470 is positioned adjacent native valve annuius VA, such that, the sidewalls of annuius groove 470 perform a clamp-like function. During ventricular- systole when the prosthetic leaflets close, the back pressure from left ventricle 124 toward left atrium 122 is relatively large. The annuius groove 470, in combination with the diameter D2 of leaflet section 430 being larger than the
diameter of the native valve annulus VA, helps the valve resist slipping into left atrium 122.
[0039] As noted above, FIGS. 4A-B omit certain structures which may be used in addition to stent 400 to form a prosthetic heart valve. For example, one or more cuffs may be attached on flange section 430 and/or at annulus groove 470 to help prevent PV leak. The number of prosthetic leaflets within the leaflet section 430 may be one, two, three, or more. The cuffs and prosthetic leaflets may be formed of the same or similar materials as described above in connection with the embodiment of FIGS, 3.A---B.
[0040] When being used in a. prosthetic heart, valve for replacing the native mitral valve of a patient, stent 400 is crimped to a. collapsed condition and positioned within a catheter or similar structure of a delivery device prior to implantation. The method of delive ing a prosthetic heart valve incorporating stent 400 may be substantially similar to that described in connection with stent 300 of FIGS. 3A-B . For example, if a trans femoral route of delivery is used, retaining tabs 460 on inflow end 410 of stent 400 may be connected to the delivery device to couple stent 400 to the delivery device until stent 400 is fully expanded. Retaining tabs (not illustrated) may be formed on outflow end 412 of stent 400, on the other hand, for retaining stent 400 in a delivery device during a transapica.1 delivery. Further, the valve 400 may be implanted such that leaflet section 430 is substantially or fully in a supraarmular position.
[0041] As noted above, although leaflet section 430 is illustrated with a substantially cylindrical shape in FIG. 4A, other shapes are possible. For example, leaflet body 430' is illustrated in FIG. 4C as having a barrel shape. In other words, barrel-shaped leaflet section 430' has a circumference that is larger (i.e., projects farther radially outward) in a
center portion than it is on either side of the center portion. The barrel-shaped body may reduce the interference of stent 400' with heart structures within a native ventricle. Further, as described above in connection with FIGS. 3A--B, leaflet section 430 may also be generally wD"-shaped to better conform to native annulus VA. For example, interference may be reduced in the sense that the relatively smooth barrel shape is less likely to "poke" or otherwise detrimentally engage with chordae tendinae or native leaflets.
[0042] Various modifications may be made to the embodiments disclosed herein without departing from the scope of the disclosure. For example, although stents and prosthetic heart valves are generally described for replacement of the mitral other bicuspid valves, variations may be made to these devices to replace tricuspid valves. Thus, the prosthetic valves may be provided with three leaflets, or more or fewer leaflets as desired. Similarly, although generally described as self- expanding prosthetic heart valves or stents, the principles described herein are also applicable to prosthetic valves that, are not self-expanding, such as balloon-expandable prosthetic valves ,
[0043] According to one embodiment of the disclosure, a stent has a collapsed, condition and an expanded condition, the stent comprising a body having an outflow end and an inflow end; and an anchoring section adjacent the inflow end and including a first annular disc and a second annular disc, the first, annular disc and the second annular disc each extending radially outwardly from the body when the stent is i the expanded condition; and/or
the first disc has a smaller diameter than the second disc when the stent is in the expanded, condition; and/or
the second disc is positioned farther away from the outflow end than the first disc; and/or
the first disc and the second disc are eac formed of a braided material; and/or
the braided material is itinol; and/or
the anchoring section includes a gap between the first disc and the second disc when the stent is in the expanded condition; and/or
the first disc is integral with the second disc; and/or the first disc and the second disc are each integral with he body ; and/or
there is substan ially no overlap between the first disc and the body when the stent, is in the collapsed condition; and/or
the first disc flares away from the outflow end and the second disc flares toward the outflow end when the stent is in the expanded condition; and/or
the first disc and the second disc each extend at an angle of about 90 degrees from a longitudinal axis of the body when the stent is in. the expanded condition; and/or
a prosthetic heart, valve having at least two prosthetic heart valve leaflets positioned, within the body.
[0044] According to another embodiment of the disclosure, a stent, has a collapsed conditio and an expanded condition, the stent comprising a body having a longitudinal axis, an outflow end, an inflow end, and a diameter in the expanded condition of the stent; an anchoring section adjacent the inflow end, and the anchoring section having a diameter in the expanded condition of the stent; and a transition section between the body and the anchoring section, the transition section in the expanded condition of the stent having a diameter that is smaller than the diameter of the body and smaller than the diameter of the anchoring section, wherein the anchoring section extends radially outwardly from the longitudinal axis
of the body when the stent is in the expanded condition; and/or
the anchoring section includes a plurality of struts forming cells; and/or
the anchoring section is integral with the body; and/or the anchoring section extends radially outwardly from the longitudinal axis of the body at an angle of between about. 80 degrees and about 100 degrees when the stent is in the expanded condition; and/or
the anchoring section extends radially outwardly from the longitudinal axis of the body at an angle of about 90 degrees when the stent is in the expanded condition; and/or
the body is substantially cylindrical; and/or
the body has a center portion between the inflow end and the outflow end, the center portion having a circumference that is larger than a circumference of the body on either side of the center portion when the stent is in the expanded condition; and/or
a prosthetic heart valve having at least two prosthetic heart valve leaflets positioned within the body.
[0045] It will be appreciated that the various dependent claims and the features set forth therein can be combined in different ways than presented in the initial claims. It will also be appreciated that the features described in connection with individual embodiments may be shared with others of the described embodiments.
Claims
1. A stent having a collapsed condition and an expanded condition; the stent comprising:
a body having an outflow and. an inflow end; and
an anchoring section adjacent the inflow end. and including a first annular disc and a second annular disc, the first annular disc and the second annular disc each extending radially outwardly from the body when the stent is in the expanded condition.
2. The stent of claim 1, wherein the first disc has a smaller diameter than the second disc when the stent is in the expanded condition,
3. The stent of claim 2 , wherein the second disc is positioned farther away from the outflow end than the first disc .
4. The stent of claim 1, wherein the first disc and the second disc are each formed of a braided material.
5. The stent, of claim 4 , wherein the braided material is Nitinol,
6. The stent of claim 1, wherein the anchoring section includes a gap between the first disc and the second disc when the stent is in the expanded condition.
7. The stent of claim 1, wherein the first disc is integral with the second disc.
8. The stent of claim 7, wherein the first disc and the second disc are each integral, with the body.
9. The stent of claim 1, wherein there is substantially no overlap between the first disc and the body when the stent is in the collapsed condition,
10. The stent of claim 1, wherein the first disc flares away from the outflow end and the second disc flares toward the outflow end when the stent is in the expanded condition,
11. The stent of claim 1, wherein the first disc and the second disc each extend at an angle of about 90 degrees from a longitudinal axis of the body when the stent is in the expanded condition.
12. A prosthetic heart valve comprising:
the stent of claim 1; and
at least two prosthetic heart valve leaflets positioned within the body.
13. The prosthetic heart valve of claim 12, wherein the at least, two prosthetic heart valve leaflets are configured to be in a supraannular position with respect to a native valve annulus when implanted.,
14. A stent, having a collapsed condition and an expanded condition, the stent comprising:
a body having a longitudinal axis, an outflow end, an inflow end, and a diameter in the expanded condition of the stent
an anchoring section adjacent the inflow end, the anchoring section having a diameter in the expanded condition of the stent; and
a transition section between the body and the anchoring section, the transition section in the expanded condition of the stent having a diameter that is smaller than the diameter of the body and smaller than the diameter of the anchoring section,
wherein the anchoring section extends radially outwardly from the longitudinal axis of the body when the stent is in the expanded condition.
1.5, The stent of claim 14, wherein the anchoring section includes a plurality of struts forming cells.
16, The stent of claim 14 , wherein the anchoring section is integral with the body.
17, The stent of claim 14, wherein the anchoring section extends radially outwardly from the longitudinal axis of the body at an angle of between about 80 degrees and about 100 degrees when the stent is in the expanded condition.
18, The stent of claim 14, wherein the anchoring section extends radially outwardly from the longitudinal axis of the body at an angle of about 90 degrees when the stent is in the expanded condition.
19, The stent of claim 14, wherein the body is substantially cylindrical.
20, The stent of claim 14, wherein the body has a center portion between the inflow end and the outflow end, the center
portion having a circumference that is larger than a circumference of the body on either side of the center portion when the stent is in the expanded condition,
21. A prosthetic heart valve comprising :
the stent of claim 14; and
at least two prosthetic heart valve leaflets positioned within the body.
22. The prosthetic heart valve of claim 21, wherein the at least two prosthetic heart valve leaflets are configured to be in a supraannuiar position with respect to a native valve annulus when implanted.
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP15727777.3A EP3145450B1 (en) | 2014-05-22 | 2015-05-20 | Stents with anchoring sections |
US15/312,005 US10500042B2 (en) | 2014-05-22 | 2015-05-20 | Stents with anchoring sections |
US16/591,694 US11311375B2 (en) | 2014-05-22 | 2019-10-03 | Stents with anchoring sections |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201462001793P | 2014-05-22 | 2014-05-22 | |
US62/001,793 | 2014-05-22 |
Related Child Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US15/312,005 A-371-Of-International US10500042B2 (en) | 2014-05-22 | 2015-05-20 | Stents with anchoring sections |
US16/591,694 Division US11311375B2 (en) | 2014-05-22 | 2019-10-03 | Stents with anchoring sections |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2015179473A1 true WO2015179473A1 (en) | 2015-11-26 |
Family
ID=53366276
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2015/031691 WO2015179473A1 (en) | 2014-05-22 | 2015-05-20 | Stents with anchoring sections |
Country Status (3)
Country | Link |
---|---|
US (2) | US10500042B2 (en) |
EP (1) | EP3145450B1 (en) |
WO (1) | WO2015179473A1 (en) |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2018083543A1 (en) * | 2016-11-04 | 2018-05-11 | Highlife Sas | Transcatheter valve prosthesis |
US10188514B2 (en) | 2016-11-04 | 2019-01-29 | Highlife Sas | Transcatheter valve prosthesis |
CN109498213A (en) * | 2017-09-14 | 2019-03-22 | 上海微创心通医疗科技有限公司 | A kind of valve bracket and valve prosthesis |
US10456247B2 (en) | 2016-11-04 | 2019-10-29 | Highlife Sas | Transcatheter valve prosthesis |
KR20200015592A (en) * | 2017-06-09 | 2020-02-12 | 상하이 마이크로포트 카디오플로우 메디테크 컴퍼니 리미티드 | Artificial tricuspid valve, artificial tricuspid valve and its stents |
US10736739B2 (en) | 2016-11-04 | 2020-08-11 | Highlife Sas | Transcatheter valve prosthesis |
Families Citing this family (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8579964B2 (en) | 2010-05-05 | 2013-11-12 | Neovasc Inc. | Transcatheter mitral valve prosthesis |
US9554897B2 (en) | 2011-04-28 | 2017-01-31 | Neovasc Tiara Inc. | Methods and apparatus for engaging a valve prosthesis with tissue |
US9308087B2 (en) | 2011-04-28 | 2016-04-12 | Neovasc Tiara Inc. | Sequentially deployed transcatheter mitral valve prosthesis |
US9345573B2 (en) | 2012-05-30 | 2016-05-24 | Neovasc Tiara Inc. | Methods and apparatus for loading a prosthesis onto a delivery system |
US9572665B2 (en) | 2013-04-04 | 2017-02-21 | Neovasc Tiara Inc. | Methods and apparatus for delivering a prosthetic valve to a beating heart |
CN108882981B (en) | 2016-01-29 | 2021-08-10 | 内奥瓦斯克迪亚拉公司 | Prosthetic valve for preventing outflow obstruction |
US20180140419A1 (en) | 2016-11-21 | 2018-05-24 | Neovasc Tiara Inc. | Methods and systems for rapid retraction of a transcatheter heart valve delivery system |
US10653523B2 (en) | 2017-01-19 | 2020-05-19 | 4C Medical Technologies, Inc. | Systems, methods and devices for delivery systems, methods and devices for implanting prosthetic heart valves |
US10561495B2 (en) | 2017-01-24 | 2020-02-18 | 4C Medical Technologies, Inc. | Systems, methods and devices for two-step delivery and implantation of prosthetic heart valve |
CA3073834A1 (en) | 2017-08-25 | 2019-02-28 | Neovasc Tiara Inc. | Sequentially deployed transcatheter mitral valve prosthesis |
US20190201192A1 (en) * | 2018-01-02 | 2019-07-04 | 4C Medical Technologies, Inc. | Stent features and methods to aid with apposition and alignment to native anatomy, mitigation of paravalvular leak and functional efficiency of prosthetic heart valve |
US11458287B2 (en) * | 2018-01-20 | 2022-10-04 | V-Wave Ltd. | Devices with dimensions that can be reduced and increased in vivo, and methods of making and using the same |
US11857441B2 (en) | 2018-09-04 | 2024-01-02 | 4C Medical Technologies, Inc. | Stent loading device |
CN113271890A (en) | 2018-11-08 | 2021-08-17 | 内奥瓦斯克迪亚拉公司 | Ventricular deployment of transcatheter mitral valve prosthesis |
US11666464B2 (en) | 2019-01-28 | 2023-06-06 | Tensor Flow Ventures Llc | Magnetic stent and stent delivery |
US20200237539A1 (en) * | 2019-01-28 | 2020-07-30 | Spiros Manolidis | Stent and stent delivery for vascular surgery |
JP7438236B2 (en) | 2019-04-01 | 2024-02-26 | ニオバスク ティアラ インコーポレイテッド | Controllably deployable prosthetic valve |
AU2020271896B2 (en) | 2019-04-10 | 2022-10-13 | Neovasc Tiara Inc. | Prosthetic valve with natural blood flow |
CN114025813B (en) | 2019-05-20 | 2024-05-14 | 内奥瓦斯克迪亚拉公司 | Introducer with hemostatic mechanism |
CA3143344A1 (en) | 2019-06-20 | 2020-12-24 | Neovasc Tiara Inc. | Low profile prosthetic mitral valve |
US11931253B2 (en) | 2020-01-31 | 2024-03-19 | 4C Medical Technologies, Inc. | Prosthetic heart valve delivery system: ball-slide attachment |
EP4112008A4 (en) * | 2021-01-20 | 2024-03-20 | Shanghai Newmed Medical Co Ltd | Interventional artificial heart valve and medical apparatus |
CN113081394B (en) * | 2021-04-12 | 2022-08-05 | 苏州茵络医疗器械有限公司 | Artificial heart valve |
CN114271992B (en) * | 2021-12-15 | 2022-09-02 | 中国医学科学院阜外医院 | Self-expanding valve delivered through femoral artery access suitable for aortic valve regurgitation |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE102005052628A1 (en) * | 2005-11-04 | 2007-05-10 | Jen.Cardiotec Gmbh | Self-expanding, flexible wire mesh with integrated valve prosthesis for the transvascular heart valve replacement |
EP1849440A1 (en) * | 2006-04-28 | 2007-10-31 | Younes Boudjemline | Vascular stents with varying diameter |
US20110029072A1 (en) * | 2009-08-03 | 2011-02-03 | Shlomo Gabbay | Heart valve prosthesis and method of implantation thereof |
WO2012095116A1 (en) * | 2011-01-11 | 2012-07-19 | Hans Reiner Figulla | Valve prosthesis for replacing an atrioventricular valve of the heart |
WO2013037519A1 (en) * | 2011-09-12 | 2013-03-21 | Highlife Sas | Transcatheter valve prosthesis |
Family Cites Families (157)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3657744A (en) | 1970-05-08 | 1972-04-25 | Univ Minnesota | Method for fixing prosthetic implants in a living body |
US4491986A (en) | 1976-05-12 | 1985-01-08 | Shlomo Gabbay | Heart valve |
US4275469A (en) | 1979-12-13 | 1981-06-30 | Shelhigh Inc. | Prosthetic heart valve |
US4759758A (en) | 1984-12-07 | 1988-07-26 | Shlomo Gabbay | Prosthetic heart valve |
DE3640745A1 (en) | 1985-11-30 | 1987-06-04 | Ernst Peter Prof Dr M Strecker | Catheter for producing or extending connections to or between body cavities |
US4878906A (en) | 1986-03-25 | 1989-11-07 | Servetus Partnership | Endoprosthesis for repairing a damaged vessel |
US4994077A (en) | 1989-04-21 | 1991-02-19 | Dobben Richard L | Artificial heart valve for implantation in a blood vessel |
DK124690D0 (en) | 1990-05-18 | 1990-05-18 | Henning Rud Andersen | FAT PROTECTION FOR IMPLEMENTATION IN THE BODY FOR REPLACEMENT OF NATURAL FLEET AND CATS FOR USE IN IMPLEMENTING A SUCH FAT PROTECTION |
US5411552A (en) | 1990-05-18 | 1995-05-02 | Andersen; Henning R. | Valve prothesis for implantation in the body and a catheter for implanting such valve prothesis |
US5843167A (en) | 1993-04-22 | 1998-12-01 | C. R. Bard, Inc. | Method and apparatus for recapture of hooked endoprosthesis |
US5480423A (en) | 1993-05-20 | 1996-01-02 | Boston Scientific Corporation | Prosthesis delivery |
US5713950A (en) | 1993-11-01 | 1998-02-03 | Cox; James L. | Method of replacing heart valves using flexible tubes |
DE69419877T2 (en) | 1993-11-04 | 1999-12-16 | Bard Inc C R | Fixed vascular prosthesis |
US5415664A (en) | 1994-03-30 | 1995-05-16 | Corvita Corporation | Method and apparatus for introducing a stent or a stent-graft |
GB9522332D0 (en) | 1995-11-01 | 1996-01-03 | Biocompatibles Ltd | Braided stent |
ATE218052T1 (en) | 1995-11-27 | 2002-06-15 | Schneider Europ Gmbh | STENT FOR USE IN A PHYSICAL PASSAGE |
US7238197B2 (en) | 2000-05-30 | 2007-07-03 | Devax, Inc. | Endoprosthesis deployment system for treating vascular bifurcations |
US5855601A (en) | 1996-06-21 | 1999-01-05 | The Trustees Of Columbia University In The City Of New York | Artificial heart valve and method and device for implanting the same |
EP0850607A1 (en) | 1996-12-31 | 1998-07-01 | Cordis Corporation | Valve prosthesis for implantation in body channels |
KR100573504B1 (en) | 1997-01-24 | 2006-04-26 | 파라곤 인텔렉츄얼 프라퍼티즈 엘엘씨. | Bistable spring construction for a expandable device |
US5961549A (en) | 1997-04-03 | 1999-10-05 | Baxter International Inc. | Multi-leaflet bioprosthetic heart valve |
US5954766A (en) | 1997-09-16 | 1999-09-21 | Zadno-Azizi; Gholam-Reza | Body fluid flow control device |
US5938697A (en) | 1998-03-04 | 1999-08-17 | Scimed Life Systems, Inc. | Stent having variable properties |
US5935163A (en) | 1998-03-31 | 1999-08-10 | Shelhigh, Inc. | Natural tissue heart valve prosthesis |
US7452371B2 (en) | 1999-06-02 | 2008-11-18 | Cook Incorporated | Implantable vascular device |
US6254564B1 (en) | 1998-09-10 | 2001-07-03 | Percardia, Inc. | Left ventricular conduit with blood vessel graft |
US6214036B1 (en) | 1998-11-09 | 2001-04-10 | Cordis Corporation | Stent which is easily recaptured and repositioned within the body |
DE19857887B4 (en) | 1998-12-15 | 2005-05-04 | Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. | Anchoring support for a heart valve prosthesis |
US6558414B2 (en) | 1999-02-02 | 2003-05-06 | Impra, Inc. | Partial encapsulation of stents using strips and bands |
US6090140A (en) | 1999-02-17 | 2000-07-18 | Shelhigh, Inc. | Extra-anatomic heart valve apparatus |
US6264691B1 (en) | 1999-04-23 | 2001-07-24 | Shlomo Gabbay | Apparatus and method for supporting a heart valve |
CA2381787A1 (en) | 1999-09-10 | 2001-03-22 | Patricia Ellen Thorpe | Endovascular treatment for chronic venous insufficiency |
US6440164B1 (en) | 1999-10-21 | 2002-08-27 | Scimed Life Systems, Inc. | Implantable prosthetic valve |
US8579966B2 (en) | 1999-11-17 | 2013-11-12 | Medtronic Corevalve Llc | Prosthetic valve for transluminal delivery |
FR2815844B1 (en) | 2000-10-31 | 2003-01-17 | Jacques Seguin | TUBULAR SUPPORT FOR THE PERCUTANEOUS POSITIONING OF A REPLACEMENT HEART VALVE |
US8016877B2 (en) | 1999-11-17 | 2011-09-13 | Medtronic Corevalve Llc | Prosthetic valve for transluminal delivery |
FR2800984B1 (en) | 1999-11-17 | 2001-12-14 | Jacques Seguin | DEVICE FOR REPLACING A HEART VALVE PERCUTANEOUSLY |
US7018406B2 (en) | 1999-11-17 | 2006-03-28 | Corevalve Sa | Prosthetic valve for transluminal delivery |
US20070043435A1 (en) | 1999-11-17 | 2007-02-22 | Jacques Seguin | Non-cylindrical prosthetic valve system for transluminal delivery |
US7195641B2 (en) | 1999-11-19 | 2007-03-27 | Advanced Bio Prosthetic Surfaces, Ltd. | Valvular prostheses having metal or pseudometallic construction and methods of manufacture |
US6458153B1 (en) | 1999-12-31 | 2002-10-01 | Abps Venture One, Ltd. | Endoluminal cardiac and venous valve prostheses and methods of manufacture and delivery thereof |
KR100880550B1 (en) | 2000-01-31 | 2009-01-30 | 쿠크 바이오텍, 인코포레이티드 | A valve device and a heart valve device |
EP1251805B1 (en) | 2000-02-03 | 2007-03-28 | Cook Incorporated | Implantable vascular device |
US6454799B1 (en) | 2000-04-06 | 2002-09-24 | Edwards Lifesciences Corporation | Minimally-invasive heart valves and methods of use |
US6610088B1 (en) | 2000-05-03 | 2003-08-26 | Shlomo Gabbay | Biologically covered heart valve prosthesis |
US6368348B1 (en) | 2000-05-15 | 2002-04-09 | Shlomo Gabbay | Annuloplasty prosthesis for supporting an annulus of a heart valve |
US6419695B1 (en) | 2000-05-22 | 2002-07-16 | Shlomo Gabbay | Cardiac prosthesis for helping improve operation of a heart valve |
US6869444B2 (en) | 2000-05-22 | 2005-03-22 | Shlomo Gabbay | Low invasive implantable cardiac prosthesis and method for helping improve operation of a heart valve |
WO2002022054A1 (en) | 2000-09-12 | 2002-03-21 | Gabbay S | Valvular prosthesis and method of using same |
US7510572B2 (en) | 2000-09-12 | 2009-03-31 | Shlomo Gabbay | Implantation system for delivery of a heart valve prosthesis |
US20020036220A1 (en) | 2000-09-26 | 2002-03-28 | Shlomo Gabbay | Curved implantable sheath and method of making same |
US6783556B1 (en) | 2000-09-26 | 2004-08-31 | Shlomo Gabbay | System and method for making a calotte-shaped implantable sheath |
US6685625B2 (en) | 2000-09-26 | 2004-02-03 | Shlomo Gabbay | Curved implantable sheath and method of making same |
US6517576B2 (en) | 2000-12-11 | 2003-02-11 | Shlomo Gabbay | Implantable patch prosthesis having one or more cusps for improved competency |
WO2002047575A2 (en) | 2000-12-15 | 2002-06-20 | Angiomed Gmbh & Co. Medizintechnik Kg | Stent with valve |
US6468660B2 (en) | 2000-12-29 | 2002-10-22 | St. Jude Medical, Inc. | Biocompatible adhesives |
US6623518B2 (en) | 2001-02-26 | 2003-09-23 | Ev3 Peripheral, Inc. | Implant delivery system with interlock |
WO2002067782A2 (en) | 2001-02-26 | 2002-09-06 | Ev3 Peripheral, Inc. | Implant delivery system with interlock |
US7556646B2 (en) | 2001-09-13 | 2009-07-07 | Edwards Lifesciences Corporation | Methods and apparatuses for deploying minimally-invasive heart valves |
DE10121210B4 (en) | 2001-04-30 | 2005-11-17 | Universitätsklinikum Freiburg | Anchoring element for the intraluminal anchoring of a heart valve replacement and method for its production |
FR2828091B1 (en) | 2001-07-31 | 2003-11-21 | Seguin Jacques | ASSEMBLY ALLOWING THE PLACEMENT OF A PROTHETIC VALVE IN A BODY DUCT |
US20080021552A1 (en) | 2001-10-09 | 2008-01-24 | Shlomo Gabbay | Apparatus To Facilitate Implantation |
US6893460B2 (en) | 2001-10-11 | 2005-05-17 | Percutaneous Valve Technologies Inc. | Implantable prosthetic valve |
DE10221076A1 (en) | 2002-05-11 | 2003-11-27 | Ruesch Willy Gmbh | stent |
US7137184B2 (en) | 2002-09-20 | 2006-11-21 | Edwards Lifesciences Corporation | Continuous heart valve support frame and method of manufacture |
US6814746B2 (en) | 2002-11-01 | 2004-11-09 | Ev3 Peripheral, Inc. | Implant delivery system with marker interlock |
FR2847800B1 (en) | 2002-11-28 | 2005-10-14 | Perouse Laboratoires | INTERCHANGEABLE PROTHETIC VALVE |
FR2850008A1 (en) | 2003-01-17 | 2004-07-23 | Daniel Roux | Vascular prosthesis has tube and collar for adapting to blood vessel ends of different diameters |
DE602004015261D1 (en) | 2003-03-20 | 2008-09-04 | Aortech Internat Plc Bellshill | VALVE |
US8221492B2 (en) | 2003-04-24 | 2012-07-17 | Cook Medical Technologies | Artificial valve prosthesis with improved flow dynamics |
US7717952B2 (en) | 2003-04-24 | 2010-05-18 | Cook Incorporated | Artificial prostheses with preferred geometries |
US7201772B2 (en) | 2003-07-08 | 2007-04-10 | Ventor Technologies, Ltd. | Fluid flow prosthetic device |
US7160322B2 (en) | 2003-08-13 | 2007-01-09 | Shlomo Gabbay | Implantable cardiac prosthesis for mitigating prolapse of a heart valve |
US10219899B2 (en) | 2004-04-23 | 2019-03-05 | Medtronic 3F Therapeutics, Inc. | Cardiac valve replacement systems |
US20060259137A1 (en) | 2003-10-06 | 2006-11-16 | Jason Artof | Minimally invasive valve replacement system |
US9005273B2 (en) | 2003-12-23 | 2015-04-14 | Sadra Medical, Inc. | Assessing the location and performance of replacement heart valves |
US8182528B2 (en) | 2003-12-23 | 2012-05-22 | Sadra Medical, Inc. | Locking heart valve anchor |
US8343213B2 (en) | 2003-12-23 | 2013-01-01 | Sadra Medical, Inc. | Leaflet engagement elements and methods for use thereof |
US20050137686A1 (en) | 2003-12-23 | 2005-06-23 | Sadra Medical, A Delaware Corporation | Externally expandable heart valve anchor and method |
US8840663B2 (en) | 2003-12-23 | 2014-09-23 | Sadra Medical, Inc. | Repositionable heart valve method |
US8828078B2 (en) | 2003-12-23 | 2014-09-09 | Sadra Medical, Inc. | Methods and apparatus for endovascular heart valve replacement comprising tissue grasping elements |
AU2003299404A1 (en) | 2003-12-23 | 2005-08-11 | Laboratoires Perouse | Kit which is intended to be implanted in a conduit |
US7311730B2 (en) | 2004-02-13 | 2007-12-25 | Shlomo Gabbay | Support apparatus and heart valve prosthesis for sutureless implantation |
US7247167B2 (en) | 2004-02-19 | 2007-07-24 | Shlomo Gabbay | Low profile heart valve prosthesis |
ITTO20040135A1 (en) | 2004-03-03 | 2004-06-03 | Sorin Biomedica Cardio Spa | CARDIAC VALVE PROSTHESIS |
JP2007535342A (en) | 2004-03-11 | 2007-12-06 | パーキュテイニアス カルディオバスキュラー ソリューションズ ピー・ティー・ワイ リミテッド | Percutaneous prosthetic heart valve |
US7374573B2 (en) | 2004-05-03 | 2008-05-20 | Shlomo Gabbay | System and method for improving ventricular function |
US20050256566A1 (en) | 2004-05-03 | 2005-11-17 | Shlomo Gabbay | Apparatus and method for improving ventricular function |
US20060122692A1 (en) | 2004-05-10 | 2006-06-08 | Ran Gilad | Stent valve and method of using same |
US20060008497A1 (en) | 2004-07-09 | 2006-01-12 | Shlomo Gabbay | Implantable apparatus having improved biocompatibility and process of making the same |
FR2874812B1 (en) | 2004-09-07 | 2007-06-15 | Perouse Soc Par Actions Simpli | INTERCHANGEABLE PROTHETIC VALVE |
JP2008514345A (en) | 2004-10-02 | 2008-05-08 | クリストフ・ハンス・フーバー | Device for treating or replacing a heart valve or surrounding tissue without requiring full cardiopulmonary support |
US8562672B2 (en) | 2004-11-19 | 2013-10-22 | Medtronic, Inc. | Apparatus for treatment of cardiac valves and method of its manufacture |
WO2006069094A1 (en) | 2004-12-20 | 2006-06-29 | Cook Incorporated | Intraluminal support frame and medical devices including the support frame |
AU2005323327B2 (en) | 2005-01-05 | 2009-11-05 | The Cleveland Clinic Foundation | Method for fixing tissue |
DE102005003632A1 (en) | 2005-01-20 | 2006-08-17 | Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. | Catheter for the transvascular implantation of heart valve prostheses |
ITTO20050074A1 (en) | 2005-02-10 | 2006-08-11 | Sorin Biomedica Cardio Srl | CARDIAC VALVE PROSTHESIS |
US7331991B2 (en) | 2005-02-25 | 2008-02-19 | California Institute Of Technology | Implantable small percutaneous valve and methods of delivery |
SE531468C2 (en) | 2005-04-21 | 2009-04-14 | Edwards Lifesciences Ag | An apparatus for controlling blood flow |
EP3266414A1 (en) | 2005-05-12 | 2018-01-10 | Covidien LP | Implant delivery system with interlocked rx port orientation |
US7914569B2 (en) | 2005-05-13 | 2011-03-29 | Medtronics Corevalve Llc | Heart valve prosthesis and methods of manufacture and use |
US7799072B2 (en) * | 2005-05-20 | 2010-09-21 | The Cleveland Clinic Foundation | Apparatus and methods for repairing the function of a diseased valve and method for making same |
US10092429B2 (en) | 2005-08-22 | 2018-10-09 | Incept, Llc | Flared stents and apparatus and methods for delivering them |
WO2007013999A2 (en) | 2005-07-21 | 2007-02-01 | Florida International University | Collapsible heart valve with polymer leaflets |
US8790396B2 (en) | 2005-07-27 | 2014-07-29 | Medtronic 3F Therapeutics, Inc. | Methods and systems for cardiac valve delivery |
WO2007016097A2 (en) | 2005-07-27 | 2007-02-08 | Georgia Tech Research Corporation | Implantable prosthetic vascular valve |
US20070067029A1 (en) | 2005-09-16 | 2007-03-22 | Shlomo Gabbay | Support apparatus to facilitate implantation of cardiac prosthesis |
US8092525B2 (en) | 2005-10-26 | 2012-01-10 | Cardiosolutions, Inc. | Heart valve implant |
EP1948088A2 (en) | 2005-11-18 | 2008-07-30 | Innovia LLC | Trileaflet heart valve |
US20070213813A1 (en) | 2005-12-22 | 2007-09-13 | Symetis Sa | Stent-valves for valve replacement and associated methods and systems for surgery |
KR20080103510A (en) | 2005-12-22 | 2008-11-27 | 시메티스 에스에이 | Stent-valves for valve replacement and associated methods and systems for surgery |
US8075615B2 (en) | 2006-03-28 | 2011-12-13 | Medtronic, Inc. | Prosthetic cardiac valve formed from pericardium material and methods of making same |
US7524331B2 (en) | 2006-04-06 | 2009-04-28 | Medtronic Vascular, Inc. | Catheter delivered valve having a barrier to provide an enhanced seal |
US20070244545A1 (en) | 2006-04-14 | 2007-10-18 | Medtronic Vascular, Inc. | Prosthetic Conduit With Radiopaque Symmetry Indicators |
AU2007255072A1 (en) | 2006-05-30 | 2007-12-13 | Cook Incorporated | Artificial valve prosthesis |
US20080097595A1 (en) | 2006-08-22 | 2008-04-24 | Shlomo Gabbay | Intraventricular cardiac prosthesis |
US8348995B2 (en) | 2006-09-19 | 2013-01-08 | Medtronic Ventor Technologies, Ltd. | Axial-force fixation member for valve |
US7534261B2 (en) | 2006-10-02 | 2009-05-19 | Edwards Lifesciences Corporation | Sutureless heart valve attachment |
CN101641061B (en) | 2006-12-06 | 2013-12-18 | 美顿力科尔瓦有限责任公司 | System and method for transapical delivery of annulus anchored self-expanding valve |
FR2909857B1 (en) | 2006-12-14 | 2009-03-06 | Perouse Soc Par Actions Simpli | Endovalve. |
US8236045B2 (en) | 2006-12-22 | 2012-08-07 | Edwards Lifesciences Corporation | Implantable prosthetic valve assembly and method of making the same |
US20100087907A1 (en) | 2007-02-16 | 2010-04-08 | Emory University | Apparatus And Methods For Treating The Aorta |
EP2698129B1 (en) | 2007-06-04 | 2022-11-09 | St. Jude Medical, LLC | Prosthetic heart valve |
US20100168778A1 (en) | 2007-06-08 | 2010-07-01 | Braido Peter N | Devices for transcatheter prosthetic heart valve implantation and access closure |
BRPI0813773A2 (en) | 2007-06-26 | 2017-05-16 | St Jude Medical | apparatus for providing a protein heart valve in a patient. |
US8728154B2 (en) | 2007-08-24 | 2014-05-20 | St. Jude Medical, Inc. | Prosthetic aortic heart valves |
DE202008018582U1 (en) | 2007-09-26 | 2016-02-11 | St. Jude Medical, Inc. | Foldable heart valve prostheses |
US8784481B2 (en) | 2007-09-28 | 2014-07-22 | St. Jude Medical, Inc. | Collapsible/expandable prosthetic heart valves with native calcified leaflet retention features |
US8454686B2 (en) | 2007-09-28 | 2013-06-04 | St. Jude Medical, Inc. | Two-stage collapsible/expandable prosthetic heart valves and anchoring systems |
US20090138079A1 (en) | 2007-10-10 | 2009-05-28 | Vector Technologies Ltd. | Prosthetic heart valve for transfemoral delivery |
EP2205184B2 (en) | 2007-11-05 | 2023-01-11 | St. Jude Medical, LLC | Collapsible/expandable prosthetic heart valves with non-expanding stent posts and retrieval features |
US20080114452A1 (en) | 2007-11-14 | 2008-05-15 | Shlomo Gabbay | Prosthesis exhibiting post-implantation size change |
AU2009205739B2 (en) | 2008-01-16 | 2014-09-25 | St. Jude Medical, Inc. | Delivery and retrieval systems for collapsible/expandable prosthetic heart valves |
MX2010009289A (en) | 2008-02-25 | 2010-10-25 | Medtronic Vascular Inc | Infundibular reducer devices. |
HUE047257T2 (en) | 2008-06-06 | 2020-04-28 | Edwards Lifesciences Corp | Low profile transcatheter heart valve |
ES2616693T3 (en) | 2008-07-15 | 2017-06-14 | St. Jude Medical, Llc | Collapsible and re-expandable prosthetic heart valve sleeve designs and complementary technological applications |
AU2009271574B2 (en) | 2008-07-15 | 2015-05-21 | St. Jude Medical, Inc. | Axially anchoring collapsible and re-expandable prosthetic heart valves for various disease states |
DE202008009610U1 (en) | 2008-07-17 | 2008-12-11 | Nvt Ag | Prosthetic heart valve system |
EP2398421B1 (en) | 2009-02-20 | 2017-09-27 | St. Jude Medical, Inc. | Devices and methods for collapsing prosthetic heart valves |
US20100217382A1 (en) | 2009-02-25 | 2010-08-26 | Edwards Lifesciences | Mitral valve replacement with atrial anchoring |
EP2400924B1 (en) | 2009-02-27 | 2017-06-28 | St. Jude Medical, Inc. | Prosthetic heart valve |
EP2810620B1 (en) | 2009-04-15 | 2022-09-14 | Edwards Lifesciences CardiAQ LLC | Vascular implant and delivery system |
EP4257083A3 (en) | 2009-11-05 | 2024-01-17 | The Trustees of the University of Pennsylvania | Valve prosthesis |
USD652927S1 (en) | 2010-09-20 | 2012-01-24 | St. Jude Medical, Inc. | Surgical stent |
USD654170S1 (en) | 2010-09-20 | 2012-02-14 | St. Jude Medical, Inc. | Stent connections |
USD653341S1 (en) | 2010-09-20 | 2012-01-31 | St. Jude Medical, Inc. | Surgical stent |
USD684692S1 (en) | 2010-09-20 | 2013-06-18 | St. Jude Medical, Inc. | Forked ends |
USD660433S1 (en) | 2010-09-20 | 2012-05-22 | St. Jude Medical, Inc. | Surgical stent assembly |
USD660432S1 (en) | 2010-09-20 | 2012-05-22 | St. Jude Medical, Inc. | Commissure point |
USD648854S1 (en) | 2010-09-20 | 2011-11-15 | St. Jude Medical, Inc. | Commissure points |
USD654169S1 (en) | 2010-09-20 | 2012-02-14 | St. Jude Medical Inc. | Forked ends |
USD653342S1 (en) | 2010-09-20 | 2012-01-31 | St. Jude Medical, Inc. | Stent connections |
USD660967S1 (en) | 2010-09-20 | 2012-05-29 | St. Jude Medical, Inc. | Surgical stent |
USD653343S1 (en) | 2010-09-20 | 2012-01-31 | St. Jude Medical, Inc. | Surgical cuff |
USD652926S1 (en) | 2010-09-20 | 2012-01-24 | St. Jude Medical, Inc. | Forked end |
US9636222B2 (en) * | 2013-03-12 | 2017-05-02 | St. Jude Medical, Cardiology Division, Inc. | Paravalvular leak protection |
US9393111B2 (en) * | 2014-01-15 | 2016-07-19 | Sino Medical Sciences Technology Inc. | Device and method for mitral valve regurgitation treatment |
-
2015
- 2015-05-20 EP EP15727777.3A patent/EP3145450B1/en active Active
- 2015-05-20 US US15/312,005 patent/US10500042B2/en active Active
- 2015-05-20 WO PCT/US2015/031691 patent/WO2015179473A1/en active Application Filing
-
2019
- 2019-10-03 US US16/591,694 patent/US11311375B2/en active Active
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE102005052628A1 (en) * | 2005-11-04 | 2007-05-10 | Jen.Cardiotec Gmbh | Self-expanding, flexible wire mesh with integrated valve prosthesis for the transvascular heart valve replacement |
EP1849440A1 (en) * | 2006-04-28 | 2007-10-31 | Younes Boudjemline | Vascular stents with varying diameter |
US20110029072A1 (en) * | 2009-08-03 | 2011-02-03 | Shlomo Gabbay | Heart valve prosthesis and method of implantation thereof |
WO2012095116A1 (en) * | 2011-01-11 | 2012-07-19 | Hans Reiner Figulla | Valve prosthesis for replacing an atrioventricular valve of the heart |
WO2013037519A1 (en) * | 2011-09-12 | 2013-03-21 | Highlife Sas | Transcatheter valve prosthesis |
Cited By (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN110049746B (en) * | 2016-11-04 | 2021-11-12 | 高品质生活简化股份公司 | Transcatheter valve prosthesis |
WO2018083543A1 (en) * | 2016-11-04 | 2018-05-11 | Highlife Sas | Transcatheter valve prosthesis |
US11376121B2 (en) | 2016-11-04 | 2022-07-05 | Highlife Sas | Transcatheter valve prosthesis |
AU2017353944B2 (en) * | 2016-11-04 | 2022-06-30 | Highlife Sas | Transcatheter valve prosthesis |
CN110049746A (en) * | 2016-11-04 | 2019-07-23 | 高品质生活简化股份公司 | Through conduit valve prosthesis |
US10456247B2 (en) | 2016-11-04 | 2019-10-29 | Highlife Sas | Transcatheter valve prosthesis |
JP2019533538A (en) * | 2016-11-04 | 2019-11-21 | ハイライフ エスエーエス | Transcatheter valve |
JP7027417B2 (en) | 2016-11-04 | 2022-03-01 | ハイライフ エスエーエス | Transcatheter artificial valve |
US10195027B2 (en) | 2016-11-04 | 2019-02-05 | Highlife Sas | Transcatheter valve prosthesis |
US10188514B2 (en) | 2016-11-04 | 2019-01-29 | Highlife Sas | Transcatheter valve prosthesis |
US11141266B2 (en) | 2016-11-04 | 2021-10-12 | Highlife Sas | Transcatheter valve prosthesis |
US10736739B2 (en) | 2016-11-04 | 2020-08-11 | Highlife Sas | Transcatheter valve prosthesis |
EP3636223B1 (en) | 2017-06-09 | 2023-02-22 | Shanghai MicroPort CardioFlow Medtech Co., Ltd. | Bicuspid valve prosthesis, tricuspid valve prosthesis, and stent therefor |
US11185410B2 (en) | 2017-06-09 | 2021-11-30 | Shanghai Microport Cardioflow Medtech Co., Ltd. | Bicuspid valve prosthesis, tricuspid valve prosthesis, and stent therefor |
KR102342242B1 (en) * | 2017-06-09 | 2021-12-23 | 상하이 마이크로포트 카디오플로우 메디테크 컴퍼니 리미티드 | Artificial bicuspid valve, artificial tricuspid valve and stent thereof |
KR20200015592A (en) * | 2017-06-09 | 2020-02-12 | 상하이 마이크로포트 카디오플로우 메디테크 컴퍼니 리미티드 | Artificial tricuspid valve, artificial tricuspid valve and its stents |
EP3636223A4 (en) * | 2017-06-09 | 2020-05-06 | Shanghai MicroPort CardioFlow Medtech Co., Ltd. | Bicuspid valve prosthesis, tricuspid valve prosthesis, and stent therefor |
JP2020522358A (en) * | 2017-06-09 | 2020-07-30 | シャンハイ マイクロポート カーディオフロー メドテック シーオー., エルティーディー.Shanghai Microport Cardioflow Medtech Co., Ltd. | Artificial bicuspid valve, artificial tricuspid valve and their stents |
CN109498213A (en) * | 2017-09-14 | 2019-03-22 | 上海微创心通医疗科技有限公司 | A kind of valve bracket and valve prosthesis |
Also Published As
Publication number | Publication date |
---|---|
US20170079785A1 (en) | 2017-03-23 |
EP3145450B1 (en) | 2019-07-17 |
US10500042B2 (en) | 2019-12-10 |
US20200030091A1 (en) | 2020-01-30 |
EP3145450A1 (en) | 2017-03-29 |
US11311375B2 (en) | 2022-04-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US11311375B2 (en) | Stents with anchoring sections | |
US11246706B2 (en) | Transcatheter mitral valve stent frames | |
US20240081999A1 (en) | Heart valve sealing devices and delivery devices therefor | |
US20220354640A1 (en) | Stent Assembly For Use in Prosthetic Heart Valves | |
US10888424B2 (en) | Prosthetic mitral valve coaptation enhancement device | |
US20180353291A1 (en) | Mitral Valve Replacement Toggle Cell Securement | |
CN108366856B (en) | Delivery system for transcatheter implantation of a heart valve prosthesis | |
US10179042B2 (en) | Heart valve repair and replacement | |
US20140371844A1 (en) | Transcatheter mitral valve and delivery system | |
US20170165053A1 (en) | Bowed Runners for Paravalvular Leak Protection | |
EP3909548B1 (en) | Transcatheter mitral valve fixation concepts | |
US11471277B2 (en) | Prosthetic tricuspid valve replacement design | |
US20160095701A1 (en) | Bi-Leaflet Mitral Valve Design | |
US20220346951A1 (en) | Telescoping capsule assembly for transcatheter valve repair and methods |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 15727777 Country of ref document: EP Kind code of ref document: A1 |
|
REEP | Request for entry into the european phase |
Ref document number: 2015727777 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2015727777 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 15312005 Country of ref document: US |
|
NENP | Non-entry into the national phase |
Ref country code: DE |